Dexcom Q3 2026 slides: margins hit multi-year high, guidance raised

Dexcom (NASDAQ:DXCM) presented third-quarter 2026 results on October 29 that showcased the glucose monitoring company’s ability to expand profitability even as revenue growth moderates, with management raising full-year guidance across multiple metrics. The company reported revenue of $1.344 billion and record non-GAAP earnings per share of $0.73, both exceeding Wall Street expectations.

The presentation revealed gross margins reaching 65.1%, the highest level since late 2022 according to management commentary, while organic revenue growth of 11% represented a deceleration from the 20% pace achieved in the prior-year quarter. Shares rose 1.73% in after-hours trading to $81.31, building on a 1.67% gain during the regular session, as investors appeared to welcome the combination of steady execution and improved profitability.

As shown in the following overview of third-quarter 2026 key metrics, Dexcom achieved balanced performance across revenue, profitability, and strategic milestones:

The company’s $1.344 billion in quarterly revenue represented 11% organic growth over the third quarter of 2025, with a notable divergence between domestic and international markets. U.S. revenue grew 14% to $969.8 million, accounting for 72% of total sales, while international revenue expanded 5% to $374.7 million. Management attributed the slower international growth to difficult comparisons with multiple reimbursement wins in the second half of 2025.

The quarter also marked publication of the CONNECT study in The New England Journal of Medicine, representing the first standalone continuous glucose monitoring data published in that journal in nearly two decades. According to management, the study produced the strongest A1C results Dexcom has generated in randomized trials.

Year-to-date free cash flow conversion reached 119%, calculated as operating cash flow minus capital expenditures divided by non-GAAP net income, demonstrating the company’s ability to convert earnings into cash.

The following quarterly trend analysis illustrates Dexcom’s consistent margin progression across multiple profitability measures:

Non-GAAP gross profit reached $875 million in the third quarter, representing a margin of 65.1%—a 380 basis point improvement from the 61.3% margin achieved in the prior-year period. This marked the highest gross margin level since late 2022, according to management commentary during the earnings call.

The margin expansion flowed through to operating income, which totaled $339.5 million on a non-GAAP basis, or 25.3% of revenue. This represented a 270 basis point improvement from the 22.6% operating margin in the third quarter of 2025. Adjusted EBITDA reached $435.2 million, or 32.4% of revenue, compared to 30.5% in the year-earlier period.

Management attributed the gross margin gains to improved freight and manufacturing efficiencies compared to 2025, along with growing contribution from the G7 15 Day product. The operating margin expansion occurred despite incremental operating expenses supporting the Ireland manufacturing facility ramp-up.

The company’s geographic revenue breakdown reveals distinct growth patterns between its largest markets. U.S. revenue of $969.8 million grew 14% year-over-year and 4% sequentially, maintaining strong momentum in the domestic market. Management noted on the earnings call that active base growth ran in the upper teens, ahead of revenue growth, suggesting continued user additions and deepening engagement. New patient starts approached record levels during the quarter.

International revenue of $374.7 million grew 5% year-over-year but remained flat sequentially. The slower international growth rate reflected challenging comparisons with prior reimbursement wins rather than underlying market weakness, according to management. On an organic basis excluding foreign exchange impacts, international growth would have been similar to the reported figure, as currency headwinds totaled just $1.7 million in the quarter.

Dexcom’s presentation highlighted several strategic priorities advancing during the quarter and beyond. The G7 15 Day extended-wear sensor continued its rollout, with management expecting the product to reach nearly 50% of the U.S. customer base by year-end 2026. The longer-wear sensor contributes to improved gross margins through manufacturing efficiencies and reduced shipping frequency.

International expansion of G7 15 Day includes a planned Canada launch in November 2026 and a Japan launch expected in early 2027. The company is also expanding its direct operations in Europe to strengthen market presence.

The over-the-counter Stelo product continues building revenue contribution from its 2025 launch, though specific revenue figures were not disclosed in the presentation. Management characterized the contribution as "building" rather than transformative at this stage.

Looking further ahead, the next-generation G8 sensor remains on track for a late 2027 or early 2028 launch. The company is also developing Dexcom Direct, a service designed to help patients navigate insurance coverage, with an expected launch in early 2027. This initiative takes on additional importance following a recent contract loss with CVS, though management indicated the affected payer represents less than 4% of U.S. revenue.

As detailed in the following guidance comparison, Dexcom raised its full-year 2026 outlook across multiple financial metrics:

The company increased its revenue guidance range to $5.20-5.25 billion from the previous $5.18-5.25 billion, implying full-year growth of 12-13%. Management noted the update reflects third-quarter outperformance partially offset by approximately $5 million in additional foreign exchange headwinds.

More significantly, Dexcom tightened and raised its profitability targets. Non-GAAP operating margin guidance moved to approximately 24% from the prior range of 23.5-24%, while adjusted EBITDA margin guidance increased to approximately 32% from 31.5-32%. Non-GAAP gross profit margin guidance remained steady at approximately 64%.

The guidance objectives section highlighted three key drivers: gross margin expansion from improved freight and manufacturing efficiencies plus growing G7 15 Day contribution; operating margin expansion despite incremental expenses for the Ireland facility; and continued advancement of Stelo with building revenue contribution.

For the fourth quarter specifically, the midpoint of the updated full-year revenue range implies growth of approximately 10%. Management expects continued margin progression into 2027, supported by G7 15 Day rollout, manufacturing efficiencies, and the normalization of Ireland facility startup costs.

The presentation included comprehensive reconciliations between GAAP and non-GAAP financial measures, demonstrating the adjustments made to arrive at the operating metrics management uses to evaluate performance. For the third quarter of 2026, GAAP gross profit totaled $864.4 million compared to non-GAAP gross profit of $875.3 million, with the difference primarily attributable to amortization of intangible assets and share-based compensation.

GAAP operating income of $327.2 million compared to non-GAAP operating income of $339.5 million, with adjustments including intellectual property litigation costs related to patent infringement litigation against Abbott Diabetes Care. GAAP net income reached $275.1 million, or $0.72 per diluted share, essentially matching the non-GAAP net income of $275.0 million and non-GAAP diluted earnings per share of $0.73.

The company’s free cash flow totaled $906.2 million for the nine months ended September 30, 2026, calculated as net cash provided by operating activities of $1,120.4 million minus purchases of property and equipment of $214.2 million. This compared to free cash flow of $885.1 million in the prior-year period.

Management commentary during the earnings call emphasized that Dexcom continues gaining market share in a stable continuous glucose monitoring category growing at low double-digit rates. Chief Executive Jake Leach stated the company "once again gained share in the quarter" while seeing "strong momentum across the CGM category."

Analysts on the earnings call focused particular attention on pricing dynamics, given competitive pressure described by rivals. Management responded that Dexcom has not experienced broad pricing degradation, with product mix and reimbursement strategy maintaining stable pricing in competitive markets. The 65.1% gross margin—the highest since late 2022—provided tangible evidence supporting this assertion.

The recent loss of preferred access with CVS emerged as a topic of investor concern, though management characterized the financial impact as limited. The affected payer represents less than 4% of U.S. revenue, and most patients should retain access through alternative channels including durable medical equipment coverage. The planned Dexcom Direct service aims to reduce patient disruption by helping them understand coverage options.

The publication of the CONNECT study in The New England Journal of Medicine subsequent to the quarter represents a significant validation of Dexcom’s clinical value proposition. Management described the study as producing the strongest A1C results in the company’s randomized trial history and noted the publication’s rarity—the first standalone CGM data in that journal in nearly two decades.

The clinical evidence may prove particularly relevant for an anticipated Centers for Medicare & Medicaid Services decision on coverage for type 2 diabetes patients not using insulin. Management indicated it still expects a CMS decision in 2026 with potential implementation in mid-2027. The CONNECT data could influence the next update to clinical standards governing such coverage decisions.

Beyond Medicare expansion, the clinical evidence supports Dexcom’s broader market development efforts, including the Smart B